{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T05:23:07Z","timestamp":1772256187908,"version":"3.50.1"},"reference-count":55,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IRDR"],"published-print":{"date-parts":[[2026,2,25]]},"DOI":"10.5582\/irdr.2025.01061","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T22:07:34Z","timestamp":1765318054000},"page":"45-53","source":"Crossref","is-referenced-by-count":0,"title":["Current status and challenges of biologic targeted therapy for myasthenia gravis in China"],"prefix":"10.5582","volume":"15","author":[{"given":"Shengying","family":"Gu","sequence":"first","affiliation":[{"name":"Department of Neurology and Rare Disease Center, Huashan Hospital, Fudan University, Shanghai, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chongbo","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurology and Rare Disease Center, Huashan Hospital, Fudan University, Shanghai, China."},{"name":"National Center for Neurological Disorders (NCND), Shanghai, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Narayanaswami P, Sanders DB, Wolfe G, <i>et al<\/i>. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021; 96:114-122.","DOI":"10.1212\/WNL.0000000000011124"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Fichtner ML, Jiang R, Bourke A, Nowak RJ, O&apos;Connor KC. Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology. Front Immunol. 2020; 11:776.","DOI":"10.3389\/fimmu.2020.00776"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Narayanaswami P, Sanders DB, Thomas L, <i>et al<\/i>. Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): A prospective cohort study. Lancet Neurol. 2024; 23:267-276.","DOI":"10.1016\/S1474-4422(24)00234-5"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Wiendl H, Abicht A, Chan A, <i>et al<\/i>. Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord. 2023; 16:17562864231213240.","DOI":"10.1177\/17562864231213240"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Schneider-Gold C, Hagenacker T, Melzer N, Ruck T. Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord. 2019; 12:1756286419832242.","DOI":"10.1177\/1756286419832242"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Neumann B, Angstwurm K, Mergenthaler P, <i>et al<\/i>. Myasthenic crisis demanding mechanical ventilation: A multicenter analysis of 250 cases. Neurology. 2020; 94:e299-e313.","DOI":"10.1212\/WNL.0000000000008688"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Piehl F, Eriksson-Dufva A, Budzianowska A, <i>et al<\/i>. Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: The RINOMAX randomized clinical trial. JAMA Neurol. 2022; 79:1105-1112.","DOI":"10.1001\/jamaneurol.2022.2887"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Nowak RJ, Benatar M, Ciafaloni E, Howard JF Jr, Leite MI, Utsugisawa K, Vissing J, Rojavin M, Li Q, Tang F, Wu Y, Rampal N, Cheng S; MINT Investigators. A phase 3 trial of inebilizumab in generalized myasthenia gravis. N Engl J Med. 2025; 392:2309-2320.","DOI":"10.1056\/NEJMoa2501561"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Howard JF Jr, Utsugisawa K, Benatar M, <i>et al<\/i>. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): A phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017; 16:976-986.","DOI":"10.1016\/S1474-4422(17)30369-1"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Vu TH, Mantegazza R, Annane D, Katsuno M, Meisel A, Nicolle MW, Bril V, Aguzzi R, Frick G, Howard JF Jr; CHAMPION MG Study Group. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: Final results from the phase 3 CHAMPION mg open-label extension. Eur J Neurol. 2025; 32:e70158.","DOI":"10.1111\/ene.70158"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Howard JF Jr, Bresch S, Genge A, <i>et al<\/i>. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): A randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 2023; 22:395-406.","DOI":"10.1016\/S1474-4422(23)00080-7"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Howard JF Jr, Bril V, Vu T, <i>et al<\/i>. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): A multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021; 20:526-536.","DOI":"10.1212\/WNL.96.15_supplement.4520"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Antozzi C, Vu T, Ramchandren S, <i>et al<\/i>. Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): A phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2025; 24:105-116.","DOI":"10.1016\/S1474-4422(24)00498-8"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Bril V, Druzdz A, Grosskreutz J, <i>et al<\/i>. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): A randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023; 22:383-394.","DOI":"10.1016\/S1474-4422(23)00077-7"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Yan C, Yue Y, Guan Y, <i>et al<\/i>. Batoclimab vs placebo for generalized myasthenia gravis: A randomized clinical trial. JAMA Neurol. 2024; 81:336-345.","DOI":"10.1001\/jamaneurol.2024.0044"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Chen J, Tian DC, Zhang C, Li Z, Zhai Y, Xiu Y, Gu H, Li H, Wang Y, Shi FD. Incidence, mortality, and economic burden of myasthenia gravis in China: A nationwide population-based study. Lancet Reg Health West Pac. 2020; 5:100063.","DOI":"10.1016\/j.lanwpc.2020.100063"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Salari N, Fatahi B, Bartina Y, Kazeminia M, Fatahian R, Mohammadi P, Shohaimi S, Mohammadi M. Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: A systematic review and meta-analysis. J Transl Med. 2021; 19:516.","DOI":"10.1186\/s12967-021-03185-7"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Yu J, Zhang H, Chen S, Dong D. Economic burden of myasthenia gravis in China: A nationwide registry-based study. Curr Med Res Opin. 2025; 41:487-493.","DOI":"10.1080\/03007995.2025.2475075"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Zhang C, Wang F, Long Z, Yang J, Ren Y, Ma Q, Li J, Wen X, Wang L, Da Y, Zhou M, Yin P, Hao J. Mortality of myasthenia gravis: A national population-based study in China. Ann Clin Transl Neurol. 2023; 10:1095-1105.","DOI":"10.1002\/acn3.51792"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Wu X, Li RY, Ye XB, Wang N. Reduced quality of life in myasthenia gravis patients: A study on 185 patients from China. Front Neurol. 2022; 13:1072861.","DOI":"10.3389\/fneur.2022.1072861"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Luo S, Xiong Y, Song Z, Lian J, Qiu Y, Zhu M, Li M, Zhou M, Hong D. A cross-sectional study on fear of progression in patients with myasthenia gravis. Sci Rep. 2025; 15:26181.","DOI":"10.1038\/s41598-025-11806-0"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Meng DD, Ruan Z, Tang YL, Ji ZH, Su Y, Xu T, Cui BZ, Ren DL, Chang T, Yang Q. Factors associated with the disease family burden of caregivers of myasthenia gravis patients in northwestern China: A cross-sectional study. J Clin Neurosci. 2024; 119:70-75.","DOI":"10.1016\/j.jocn.2023.11.024"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Oguz-Akarsu E, Lazrak SEH, Gullu G, Dinc Y, Saridas F, Karli N. Unusual presentations of myasthenia gravis and misdiagnosis. Sci Rep. 2025; 15:7516.","DOI":"10.1038\/s41598-025-91470-6"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, Melms A, Tackenberg B, Schalke B, Schneider-Gold C, Zimprich F, Meuth SG, Wiendl H. Clinical features, pathogenesis, and treatment of myasthenia gravis: A supplement to the guidelines of the German neurological society. J Neurol. 2016; 263:1473-1494.","DOI":"10.1007\/s00415-016-8045-z"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Uzawa A, Kuwabara S, Suzuki S, Imai T, Murai H, Ozawa Y, Yasuda M, Nagane Y, Utsugisawa K. Roles of cytokines and T cells in the pathogenesis of myasthenia gravis. Clin Exp Immunol. 2021; 203:366-374.","DOI":"10.1111\/cei.13546"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Li X, Zhao C. Interleukin-6 in neuroimmunological disorders: Pathophysiology and therapeutic advances with satralizumab. Autoimmun Rev. 2025; 24:103826.","DOI":"10.1016\/j.autrev.2025.103826"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Man\u00e9-Damas M, Sch\u00f6ttler AK, Marcuse F, Molenaar PC, Mohile T, Hoeijmakers JGJ, Hochstenbag M, Damoiseaux J, Maessen JG, Abdul-Hamid M, Zur Hausen A, de Baets MH, Losen M, Martinez-Martinez P. Myasthenia gravis with antibodies against the AChR, current knowledge on pathophysiology and an update on treatment strategies with special focus on targeting plasma cells. Autoimmun Rev. 2025; 24:103875.","DOI":"10.1016\/j.autrev.2025.103875"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Vergoossen DLE, Augustinus R, Huijbers MG. MuSK antibodies, lessons learned from poly-and monoclonality. J Autoimmun. 2020; 112:102488.","DOI":"10.1016\/j.jaut.2020.102488"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Lu J, Zhong H, Jing S, Wang L, Xi J, Lu J, Zhou L, Zhao C. Low-dose rituximab every 6 months for the treatment of acetylcholine receptor-positive refractory generalized myasthenia gravis. Muscle Nerve. 2020; 61:311-315.","DOI":"10.1002\/mus.26790"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Zhou Y, Yan C, Gu X, Zhou L, Lu J, Zhu W, Huan X, Luo S, Zhong H, Lin J, Lu J, Zhao C, Xi J. Short-term effect of low-dose rituximab on myasthenia gravis with muscle-specific tyrosine kinase antibody. Muscle Nerve. 2021; 63:824-830.","DOI":"10.1002\/mus.27233"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Ren J, Wang J, Liu R, Jin Y, Guo J, Yao Y, Luo J, Hao H, Gao F. Long-term efficacy and safety of low-dose rituximab in patients with refractory myasthenia gravis. Eur Neurol. 2023; 86:387-394.","DOI":"10.1159\/000534336"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Yang X, Zhang W, Chang X, Li Z, Du R, Guo J. Promising efficacy of low-dose rituximab in Muscle specific kinase antibody positive myasthenia gravis. Neurosci Lett. 2024; 818:137561.","DOI":"10.1016\/j.neulet.2023.137561"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Li H, Huang Z, Jia D, Xue H, Pan J, Zhang M, Shi K, Shi FD, Zhang C. Low-dose rituximab treatment for new-onset generalized myasthenia gravis. J Neuroimmunol. 2021; 354:577528.","DOI":"10.1016\/j.jneuroim.2021.577528"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Du Y, Li C, Hao YF, Zhao C, Yan Q, Yao D, Li L, Zhang W. Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis. J Neurol. 2022; 269:4229-4240.","DOI":"10.1007\/s00415-022-11048-4"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Gilhus NE, Andersen H, Andersen LK, Boldingh M, Laakso S, Leopoldsdottir MO, Madsen S, Piehl F, Popperud TH, Punga AR, Schirakow L, Vissing J. Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment. Eur J Neurol. 2024; 31:e16229.","DOI":"10.1111\/ene.16229"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Yin J, Zhao M, Xu X, <i>et al<\/i>. A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis. Eur J Neurol. 2024; 31:e16322.","DOI":"10.1111\/ene.16322"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Jin L, He D, Zeng Q, <i>et al<\/i>. Eculizumab in thymoma-associated myasthenia gravis: A real-world cohort study. Ther Adv Neurol Disord. 2024; 17:17562864241309431.","DOI":"10.1177\/17562864241309431"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Song J, Huan X, Chen Y, Luo Y, Zhong H, Wang Y, Yang L, Xi C, Yang Y, Xi J, Zheng J, Wu Z, Zhao C, Luo S. The safety and efficacy profile of eculizumab in myasthenic crisis: A prospective small case series. Ther Adv Neurol Disord. 2024; 17:17562864241261602.","DOI":"10.1177\/17562864241261602"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Deng Y, Luo H, Zhang C, Yang L, Wang S, Zhang X, Yan X, Yang X, Jiang Q. Case report: Eculizumab in highly active myasthenia gravis complicated by severe infections. Front Immunol. 2025; 16:1596283.","DOI":"10.3389\/fimmu.2025.1596283"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Huang Y, Wu F, Xiong Y, Huang K, Chang X, Chen X, Chen X, Zhang Q, Zou L, Fu X, Zhang H, Xu Q. Eculizumab as fast-acting rescue therapy for pembrolizumab-induced impending crisis state of myasthenia gravis: A case report. Ther Adv Neurol Disord. 2025; 18:17562864251333518.","DOI":"10.1177\/17562864251333518"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Nishimura J, Yamamoto M, Hayashi S, <i>et al<\/i>. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014; 370:632-639.","DOI":"10.1056\/NEJMoa1311084"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Guo R, Sun C, Huang X, Hao S, Wang Q, Ruan Z, Gao T, Tang Y, Cao X, Liu Y, Li Z, Chang T. Efficacy and safety of efgartigimod versus intravenous immunoglobulin in early intervention of acetylcholine receptor antibody-positive impending myasthenic crisis: A retrospective cohort study. Neurotherapeutics. 2025; pp:e00730.","DOI":"10.1016\/j.neurot.2025.e00730"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. He D, Jin L, Wang S, Zhong H, Chen H, Zhou H, Zou Z, Zhao C, Huan X, Song J, Xi J, Yan C, Luo S. Efgartigimod versus standard of care in new-onset AChR subtype generalized myasthenia gravis: A prospective cohort study. Clin Immunol. 2025; 281:110587.","DOI":"10.1016\/j.clim.2025.110587"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. He D, Zhou Y, Zhang Y, Zhang J, Yan C, Luo S, Zhao C, Xi J. Response of refractory residual ocular symptoms to efgartigimod in generalized myasthenia gravis: A real-world case series. J Neuroimmunol. 2025; 401:578558.","DOI":"10.1016\/j.jneuroim.2025.578558"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Luo S, Jiang Q, Zeng W, <i>et al<\/i>. Efgartigimod for generalized myasthenia gravis: A multicenter real-world cohort study in China. Ann Clin Transl Neurol. 2024; 11:2212-2221.","DOI":"10.1002\/acn3.52142"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Song J, Wang H, Huan X, Jiang Q, Wu Z, Yan C, Xi J, Zhao C, Feng H, Luo S. Efgartigimod as a promising add-on therapy for myasthenic crisis: A prospective case series. Front Immunol. 2024; 15:1418503.","DOI":"10.3389\/fimmu.2024.1418503"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Wang S, Zhu M, Dong J, <i>et al<\/i>. Perioperative safety and efficacy of efgartigimod for thymoma-associated myasthenia gravis: A prospective, multicenter, phase II clinical trial. J Thorac Oncol. 2025; 20:1120-1130.","DOI":"10.1016\/j.jtho.2025.04.014"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Habib AA, Zhao C, Aban I, <i>et al<\/i>. Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): A randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2025; 24:117-127.","DOI":"10.1016\/S1474-4422(24)00514-3"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Ruan Z, Tang Y, Gao T, Li C, Guo R, Sun C, Huang X, Li Z, Chang T. Efficacy and safety of tocilizumab in patients with refractory generalized myasthenia gravis. CNS Neurosci Ther. 2024; 30:e14793.","DOI":"10.1111\/cns.14793"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Jia D, Zhang F, Li H, Shen Y, Jin Z, Shi FD, Zhang C. Responsiveness to tocilizumab in anti-acetylcholine receptor-positive generalized myasthenia gravis. Aging Dis. 2024; 15:824-830.","DOI":"10.14336\/AD.2023.0528"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Zhang Y, Liu D, Zhang Z, <i>et al<\/i>. Bispecific BCMA\/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: A case report. J Neurol. 2024; 271:4655-4659.","DOI":"10.1007\/s00415-024-12367-4"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Tian DS, Qin C, Dong MH, <i>et al<\/i>. B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis. EMBO Mol Med. 2024; 16:966-987.","DOI":"10.1038\/s44321-024-00043-z"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Tarasco MC, Rinaldi E, Frangiamore R, Vanoli F, Berni A, Iacomino N, Canciello A, Andreetta F, Ciusani E, Bonanno S, Maggi L, Baggi F, Mantegazza R, Antozzi C, Cavalcante P. Unknown immunoregulatory effects of FcRn inhibition by efgartigimod in myasthenia gravis: A new mechanism of action beyond IgG reduction. Neurol Neuroimmunol Neuroinflamm. 2025; 12:e200455.","DOI":"10.1212\/NXI.0000000000200455"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Li HN, Liu J, Huang XY, Zhu L, Liu Z, Yang CS, Zhang B, Huang S, Shi FD, Cai Z, Zhang C. Single-cell atlas reveals heterogeneous response to FcRn blockade in anti-AChR antibody-positive generalised myasthenia gravis. Clin Transl Med. 2025; 15:e70436.","DOI":"10.1002\/ctm2.70436"},{"key":"55","unstructured":"55. Chinese Society of Neuroimmunology. Chinese guideline for diagnosis and treatment of myasthenia gravis (2025 edition). Chin J Neurol. 2025; 58:721-741."}],"container-title":["Intractable &amp; Rare Diseases Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/15\/1\/15_2025.01061\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:03:49Z","timestamp":1772251429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/15\/1\/15_2025.01061\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5582\/irdr.2025.01061","relation":{},"ISSN":["2186-361X","2186-3644"],"issn-type":[{"value":"2186-361X","type":"electronic"},{"value":"2186-3644","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"article-number":"2025.01061"}}